Development of a Peptide–Drug Conjugate for Prostate Cancer Therapy
- 21 April 2011
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 8 (3) , 901-912
Abstract
TGX-221 is a highly potent phosphoinositide 3-kinase β (PI3Kβ) inhibitor that holds great promise as a novel chemotherapeutic agent to treat prostate cancer. However, poor solubility and lack of targetability limit its therapeutic applications. The objective of this present study is to develop a peptide–drug conjugate to specifically deliver TGX-221 to HER2 overexpressing prostate cancer cells. Four TGX-221 derivatives with added hydroxyl groups were synthesized for peptide conjugation. Among them, TGX-D1 exhibited a similar bioactivity to TGX-221, and it was selected for conjugation with a peptide promoiety containing a HER2-targeting ligand and a prostate specific antigen (PSA) substrate linkage. From this selection, the peptide–drug conjugate was proven to be gradually cleaved by PSA to release TGX-D1. Cellular uptake of the peptide–drug conjugate was significantly higher in prostate cancer cells compared to the parent drug. Moreover, both the peptide–drug conjugate and its cleaved products demonstrated comparable activities as the parent drug TGX-D1. Our results suggest that this peptide–drug conjugate may provide a promising chemotherapy for prostate cancer patients.Keywords
This publication has 42 references indexed in Scilit:
- Targeting phosphoinositide 3-kinase—Moving towards therapyBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2008
- Evaluation of an 111In-Radiolabeled Peptide as a Targeting and Imaging Agent for ErbB-2 Receptor–Expressing Breast CarcinomasClinical Cancer Research, 2007
- FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcomeBritish Journal of Cancer, 2007
- Modulating paclitaxel bioavailability for targeting prostate cancerBioorganic & Medicinal Chemistry, 2007
- Anti-HER2 Cationic Immunoemulsion as a Potential Targeted Drug Delivery System for the Treatment of Prostate CancerCancer Research, 2007
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 2006
- Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patientsBritish Journal of Cancer, 2006
- NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN lossCancer Cell, 2006
- PTEN and GSK3β: key regulators of progression to androgen-independent prostate cancerOncogene, 2006
- Phosphoinositide 3-kinase: From viral oncoprotein to drug targetVirology, 2006